全部 标题 作者
关键词 摘要

OALib Journal期刊
ISSN: 2333-9721
费用:99美元

查看量下载量

相关文章

更多...

Reversible Chronic Interstitial Nephritis Induced by Tacrolimus
—Tacrolimus Chronic Interstitial Nephritis

DOI: 10.4236/ojneph.2023.131001, PP. 1-5

Keywords: Calcineurin Inhibitors, Mycophenolate Mofetil, Tacrolimus, Interstitial Nephritis, Minimal Change Disease, Nephrotic Syndrome

Full-Text   Cite this paper   Add to My Lib

Abstract:

Calcineurin inhibitors (CNI) are potent immunosuppressive agents in prophylaxis against graft rejection and autoimmune diseases including primary glomerulopathies. Previous research showed reversible; acute afferent arteriolar vasculopathy and irreversible chronic interstitial fibrosis associated with CNI nephrotoxicity. In this case report we describe a patient, with minimal change disease, that had developed chronic and progressive renal disease while receiving therapeutic dose of Tacrolimus. His serum creatinine had reached 537 umol/L and his nephrotic state worsened. Kidney biopsy showed chronic interstitial nephritis. Tacrolimus was discontinued and he was treated with 1 mg/kg prednisone in addition to Mycophenolate mofetil (MMF) 1 g twice daily. By the 2nd month; serum creatinine returned to normal and by the 3rd month serum albumin too. After 1 month of therapy; the dose of Prednisone was tapered down gradually till 5 mg daily by the end of 3rd month. Moreover, the dose of MMF was reduced to 500 mg X2 by the end of 3rd month. After 2 years of follow up; he remained stable and without relapse of NS or renal failure. In conclusion, reversible renal disease, due to chronic interstitial nephritis can be induced by CNI which is amenable to treatment with Prednisone and MMF.

References

[1]  Azzi, J.R., Sayegh, M.H. and Mallat, S.G. (2013) Calcineurin Inhibitors: 40 Years Later, Can’t Live Without. The Journal of Immunology, 191, 5785-5791.
https://doi.org/10.4049/jimmunol.1390055
[2]  Rovin, B.H., Adler, S.G., Barratt, J., Bridoux, F., Burdge, K.A., et al. (2021) Executive Summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. Kidney International, 100, 753-779.
https://doi.org/10.1016/j.kint.2021.05.015
[3]  Bierer, B.E., Holländer, G., Fruman, D. and Burakoff, S.J. (1993) Cyclosporin A and FK506: Molecular Mechanisms of Immunosuppression and Probes for Transplantation Biology. Current Opinion in Immunology, 5, 763-773.
https://doi.org/10.1016/0952-7915(93)90135-F
[4]  Barbarino, J.M., Staatz, C.E., Venkataramanan, R., Klein, T.E. and Altman, R.B. (2013) PharmGKB Summary: Cyclosporine and Tacrolimus Pathways. Pharmacogenetics and Genomics, 23, 563-585.
https://doi.org/10.1097/FPC.0b013e328364db84
[5]  Issa, N., Kukla, A. and Ibrahim, H.N. (2013) Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence. American Journal of Nephrology, 37, 602-612.
https://doi.org/10.1159/000351648
[6]  Stegall, M.D., Cornell, L.D., Park, W.D., Smith, B.H. and Cosio, F.G. (2018) Renal Allograft Histology at 10 Years after Transplantation in the Tacrolimus Era: Evidence of Pervasive Chronic Injury. American Journal of Transplantation, 18, 180-188.
https://doi.org/10.1111/ajt.14431
[7]  Lusco, M.A., Fogo, A.B., Najafian, B. and Alpers, C.E. (2017) AJKD Atlas of Renal Pathology: Calcineurin Inhibitor Nephrotoxicity. American Journal of Kidney Diseases, 69, e21-e22.
https://doi.org/10.1053/j.ajkd.2017.02.003
[8]  Querfeld, U. and Weber, L.T. (2018) Mycophenolate Mofetil for Sustained Remission in Nephrotic Syndrome. Pedi-atric Nephrology, 33, 2253-2265.
https://doi.org/10.1007/s00467-018-3970-y
[9]  He, X., Smeets, R.L., Koenen, H.J., Vink, P.M., Wagenaars, J., Boots, A.M. and Joosten, I. (2011) Mycophenolic Acid-Mediated Suppression of Human CD4+ T Cells: More than Mere Guanine Nucleotide Deprivation. American Journal of Transplantation, 11, 439-449.
https://doi.org/10.1111/j.1600-6143.2010.03413.x
[10]  El-Reshaid, K., Al-Bader, S. and Sallam, H.T. (2022) The Beneficial Effect of Combination of Mycophenolate with Low-Dose Corticosteroids and Calcineurin-Inhibitor as well as Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Blocker in Induction and Maintenance of Remission in Corticosteroidandand Rituximab-Resistant Minimal Change Nephrotic Syndrome in Adults. Open Journal of Nephrology, 12, 15-22.
https://doi.org/10.4236/ojneph.2022.121002
[11]  Hackl, A., Becker, J.U., Körner, L.M., et al. (2018) Mycophenolate Mofetil Following Glucocorticoid Treatment in Henoch-Schönlein Purpura Nephritis: The Role of Early Initiation and Therapeutic Drug Monitoring. Pediatric Nephrology, 33, 619-629.
https://doi.org/10.1007/s00467-017-3846-6

Full-Text

comments powered by Disqus

Contact Us

service@oalib.com

QQ:3279437679

WhatsApp +8615387084133

WeChat 1538708413